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The concentration of lead in bone appar-
ently increases steadily throughout life. By
the time a woman reaches the age of
menopause she can expect to have a bone
lead content of about 12 jsg/g mineral in
cortical bone, with somewhat higher levels
in trabecular bone (1). Because about 95%
ofbody lead resides in the skeleton, a typi-
cal endogenous lead burden for a meno-
pausal woman will be 30 mg.
Endogenous lead has access to the circu-
lation through the normal processes ofmin-
eral exchange and bone turnover. The con-
centration of lead in bone can decrease if
the rate of lead transfer from bone to the
circulation during mineral exchange and
bone turnover is greater than the rate of
lead transfer from the circulation to bone.
Such a situation can best be achieved by
reducing the rate of ingestion of lead such
that the concentration of lead in newly
formed bone will fall and the amount of
lead available for exchange from the circula-
tion is reduced.
Recent declines in blood lead levels
achieved by reducing environmental lead
exposures (2) should also produce reduc-
tions in bone lead content by decreasing
uptake oflead into bone. Superimposed on
this effect, the increase in bone resorption
associated with menopause should increase
the release of lead from bone. Since hor-
mone replacement therapy (HRT) opposes
the increase in both bone resorption and
mineral exchange, it would be expected
that HRT would maintain bone lead con-
centration and suppress the transfer of
endogenous lead to the circulation.
Women on HRT should have higher con-
centrations ofbone lead and lower concen-
trations of plasma lead. To test this possi-
bility, we compared the concentrations of
lead in bone, serum, urine, and whole
blood for subjects who were either on cal-
cium supplementation or on HRT plus
calcium supplementation.
Materials and Methods
The subjects who volunteered for these
measurements were participants in a study
ofthe impact of HRT on bone mass. The
protocol for that study, which has been
described previously (3), was approved by
the Research Advisory Committee of the
Faculty of Health Sciences, McMaster
University. White women, who were typi-
cally between 1 and 5 years post-
menopause, were recruited from the local
community and placed on calcium supple-
mentation (500 mg/day). Six months later
each woman chose either to add HRT to
the calcium supplementation or to remain
on calcium alone. Those given HRT
received either a low-dose, continuous or a
moderate-dose, cyclical regime. The low-
dose regime consisted of 0.3 mg/day
equine estrogen (Premarin) and 2.5
mg/day medroxyprogesterone (Provera).
The moderate-dose, cyclical regime was
0.625 mg/day Premarin for days 1-25 and
5 mg/day Provera for days 16-25 of a
monthly cycle. After 2 years, the moderate-
dose, cyclical regime was changed to a mod-
erate-dose, continuous regime which con-
sisted of 0.625 mg/day Premarin and 2.5
mg/day Provera.
Longitudinal measurements of bone
mass were made at the one-third radius and
lumbar spine using photon absorptiometry
(3,4). These sites were selected as representa-
tive of cortical and trabecular bone. There
were no statistically significant differences in
age, weight, height, years since menopause,
or bone-mass variables between the three
groups at entry into the study (4). There
were also no differences between groups for
variables such as smoking, drinking, diet, or
parity (5). A questionnaire designed to iden-
tify occupational, recreational, and environ-
mental exposure to lead was administered to
each subject at the time of bone lead mea-
surement. No differences in lead exposure
could be detected between groups.
The calcium-only group consisted of23
women, 2 of whom originally chose HRT
but declined their assigned therapy and
continued on calcium only. One additional
subject was transferred to the calcium-only
group after less than 3 months on low-dose
HRT. There were 33 women who chose
calcium supplementation plus HRT.
Sixteen ofthese were on low-dose, continu-
ous HRT and 11 were on moderate-dose
HRT. The mean duration ofHRT for sub-
jects on the low-dose regime was 4.10 years
(SD = 0.22 years). For the subjects on mod-
erate-dose HRT, the mean duration was
3.90 years (SD = 0.37 years). A fourth
group of six women did not comply with
their assigned HRT regime between the
times of enrollment and the measurement
of lead concentrations. Their mean dura-
tion of exposure to hormones was 2.15
years (SD = 0.49 years).
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The lead concentrations of bone,
blood, serum, and urine were measured
during the fourth or fifth year of HRT.
Bone lead was measured at the mid-tibia
and the right calcaneus in all subjects using
the instrument described by Gordon et al.
(6). These sites are considered to be repre-
sentative of cortical and trabecular bone.
Briefly, the bone was exposed to a beam of
88-keV photons emitted from a 109Cd
source. Characteristic X-rays emitted from
any lead present in the bone are detected
by a high-purity germanium detector. At
the same time, 88-keV photons coherently
scattered by bone mineral into the detector
are monitored. With appropriate calibra-
tion, the system yields a measurement of
bone lead content in units of micrograms
of lead per gram of bone mineral. The
standard deviation ofrepeated in vivo mea-
surements is typically between 2 and 5 pg
Pb/g mineral at the tibia (7). For calcaneal
measurements the uncertainty is greater
(typically 8 pg Pb/g mineral) because a
smaller mass of bone is measured and
because the overlying tissue is thicker at the
calcaneal site compared to the tibial site.
Serum and urine lead was measured
using a technique developed by Bowins
and McNutt (8). A tracer quantity of
enriched 204Pb was added to each serum or
urine sample, which was acidified with
nitric acid. Aliquots were then volatilized
in a graphite furnace and introduced into
an inductively coupled plasma mass spec-
trometer. The technique yields a standard
deviation of 0.006 pg/dl at a lead concen-
tration of0.03 pg/dl.
Blood lead was measured by flameless
atomic absorption spectrophotometry. The
coefficient ofvariation from measurements
repeated over a 3-month period for a con-
trol sample with a lead concentration of
about 60 pg/dl was 4%.
We used one-way analysis of variance
to search for differences between groups in
the concentrations oflead in blood, serum,
and urine as well as for the bone lead con-
tent ofthe tibia and calcaneus. Two-sample
t-tests were used to test for significant dif-
ferences between subjects who had never
taken hormones and those who had com-
plied fully with their regime. Only those
subjects with complete data sets were
included in the analysis, and differences
associated with a p-value <0.05 were con-
sidered significant.
Results
As reported elsewhere (3), moderate-dose
HRT increased bone mineral mass at the
spine, while low-dose HRT eliminated a
rate of loss of 0.3 g mineral/year observed
on calcium alone. HRT produced no dif-
ferences in rates ofchange ofmineral mass
at the radius.
Complete results for whole blood and
serum lead concentrations, 24-hr urine
excretion of lead, and the lead content of
the tibia and calcaneus were obtained in 22
subjects in the calcium-only group, 15 in
the low-dose HRT group, 11 in the mod-
erate-dose HRT group, and 6 subjects in
the partial HRT group. Two serum sam-
ples, one from the calcium-only group and
one from the low-dose HRT group, were
lost to analysis due to a technical failure of
the mass spectrometer. The mean values
and standard deviations for the measured
variables are given in Table 1 for each
group ofsubjects. One-way analysis ofvari-
ance showed that tibia lead content was
significantly lower in the group ofsubjects
not taking hormones (p = 0.049). No other
statistically significant difference existed
between groups. The mean tibia lead con-
tent is shown for each group in Figure 1.
If the subjects are assigned to two
groups, one ofwhich is composed of sub-
jects who had never taken hormones (N=
22), the other of those subjects who fully
complied with their hormone replacement
regime (N= 26), a two-sample t-test shows
a significant difference in tibia bone lead (p
= 0.007) but no difference in calcaneal
bone lead (p = 0.47).
Discussion
These results suggest that postmenopausal
women who are on HRT will have a
Table 1. Mean values (SDs) forthe measured variables
Variable
Blood lead (pg/dl)
Serum lead (pg/dl)
Urine lead (pg/day)
Tibia lead (pg/g)
Calcaneus lead (pg/g)
None
(N= 22)
4.60(1.59)
0.074(0.048)
2.77 (1.70)
11.13 (6.22)
21.12(13.55)
Hormone replacementtherapya
Low dose Moderate dose
(N= 15) (N= 11)
4.08 (1.60) 5.22(3.36)
0.106 (0.065) 0.061 (0.025)
2.23(0.90) 2.93(2.20)
19.37 (8.62) 16.80(11.68)
24.02 (10.88) 23.83(14.18)
Partial HRT
(N=6)
3.35 (1.32)
0.086(0.057)
2.10 (1.78)
14.66 (8.41)
17.63(16.09)
greater skeletal lead burden than women
not on hormones. The excess lead is locat-
ed within cortical bone, rather than trabec-
ular bone, probably because the retention
time in cortical bone is at least twice that of
trabecular bone (95. This is consistent with
measures of blood lead made during the
second National Health and Nutrition
Examination Survey (NHANES II) (10).
In 849 women between 40 and 60 years of
age, blood lead concentration post-
menopause was 13.0 pg/dl, whereas in pre-
menopausal women it averaged 11.9 pg/dl.
The increased blood lead is thought to be
due to release oflead from bone as a conse-
quence of menopause-related increases in
bone turnover. In our study, hormone
replacement did not produce a significant
difference in blood lead concentration. The
average concentrations in our subjects were
approximately one-third those observed in
NHANES II but were similar to the values
reported in NHANES III (11). Hormone
replacement prevents the menopause-asso-
ciated increase in bone turnover, and lead
would be expected to remain in the skele-
ton. The menopause-related increase in
blood lead is greater for white than for
black women because the increase in bone
turnover is greater for white women (12).
Especially at risk for increased blood lead
after menopause are white women who
have had no children. This is thought to be
because skeletal lead burdens would have
been reduced by a postpartum increase in
bone turnover in lactating women (13,14),
resulting in less lead being available for
mobilization after menopause (15).
The transfer of calcium between bone
and the circulation takes place through the
processes of mineral exchange and bone
turnover. The purpose of exchange and
turnover is to release minerals to the circu-
lation, repair damaged bone, replace effete
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Figure 1. Mean tibia lead content and standard
error of the mean for postmenopausal women
who have never used hormone replacement ther-
apy (No HRT) and those who partially complied
(Part HRT) orfully complied with a low dose (Low
HRT) or moderate dose (Mod HRT) hormone
replacementregime.
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aLow dose consisted of 0.3 mg/day estrogen and 2.5 mg/day medroxyprogesterone; moderate dose con-
sisted of 0.625 mg/day estrogen on days 1-25 and 5 mg/day progesterone on days 16-25 for 2 years, then
0.625 mg/day estrogen and 2.5 mg/day progesterone for 2 years; partial therapy included women who did
not complywith their assigned regime. See Materials and Methods for details.
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bone and reorganize bone in response to
altered mechanical environments. It has
been estimated that each day the mass of
calcium involved in exchange is about 10
times the mass of calcium involved in
turnover (16). In recently proposed com-
partmental models oflead metabolism, the
assumption is made that these same
processes are responsible for the movement
of lead between the circulation and bone
(17,18). Lead on bone surfaces is consid-
ered to be rapidly exchangeable, whereas
lead distributed throughout the bone vol-
ume is in exchange with bone surface lead.
In reality, not all bone lead will be equally
exchangeable with circulating lead, but
there is likely to be a spectrum of accessi-
bility ranging from freely exchangeable to
non-exchangeable. The latter will corre-
spond to lead fixed within bone crystals
and available only after osteoclastic resorp-
tion ofbone (19).
The exchange ofcalcium between bone
and the circulation is under the influence
ofparathyroid hormone (20). The sensitiv-
ity ofpostmenopausal bone to the effects of
parathyroid hormone is reduced by estro-
gen replacement. That is, for the same
parathyroid hormone concentration, the
estrogen replete woman will have lower
serum calcium (21,22). The rate ofresorp-
tion of bone is decreased by estrogen
through a reduction in the activation fre-
quency of new remodeling cycles with an
increase in the mean age of the bone
(23-25). It is known that elements that are
bone-volume seekers such as lead and the
alkaline earth elements are retained to a
greater extent in older bone than in newly
formed bone (26).
The relative contributions of exchange
and turnover to the reduction in bone lead
content after menopause can be estimated
from our data. In premenopausal women
the rate of bone turnover is about 150 mg
Ca/day, and, without hormone replace-
ment, bone resorption increases by about
20% after menopause (27). If we assume
that hormone replacement completely pre-
vents any rise in bone resorption, then
HRT should prevent the turnover ofabout
30 mg calcium each day. During the course
of4 years ofHRT, the total mass ofcalci-
um protected could amount to about 44 g
of calcium or about 100 g bone mineral.
Thus, the mass oflead protected by a hor-
mone-induced reduction of bone turnover
could amount to almost 2 mg. The
observed difference in concentration at the
tibia between the calcium-only group and
the HRT groups is about 6 j'g/g bone min-
eral or, for a bone mass of 2000 g, a total
mass oflead of 12 mg. Thus, about 10 mg
of lead remains in bone because of a hor-
mone-induced reduction in exchange. It
should be noted that this estimate neglects
the lead present in trabecular bone and also
any differences in bone mass produced by
HRT.
This study is an observational report on
a convenience sample ofsubjects. It is lim-
ited by its cross-sectional nature, and it is
conceivable that differences in bone lead
may have existed before HRT was started.
The fraction of bone lead released after
menopause may be greater in some women
than indicated by this work. All women in
this study took calcium supplementation,
and it is possible that in subjects with calci-
um deficiency, the mass of bone involved
in exchange and turnover processes may be
even greater. In addition, hormone replace-
ment did not start immediately after
endogenous estrogen levels fell. The mean
time after menopause that women started
HRT was 3.5 years (4). Consequently, all
subjects in this study suffered a period
without HRT and therefore will have lost
some lead from the bone. The woman who
is likely to release the most lead from her
skeleton is the woman who has accumulat-
ed considerable lead from her environment,
who suffers a significant perimenopause
increase in bone turnover and mineral
exchange, and who may have a poor calci-
um intake.
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Xlvih World Congress on Occupational
Safety and Health
April 22-26, 1996
Madrid, Spain
The XIVth World Congress on Occupational Safety and Health will be held in
Madrid fromApril 22 toApril 26, 1996. The organizers are the Spanish Ministry
of Labour and Social Security, through the National Institute for Occupational
Safety and Health (INSHT), the International Labour Office (ILO), Geneva, and the
International Social SecurityAssociation (ISSA), Geneva.
These World Congresses, ofwhich the first was held in Rome in 1955 and the last in New Delhi in 1993,
have had such venues as Brussels, Paris, London, Zagreb, Vienna, Dublin, Bucharest, Amsterdam,
Ottawa, Stockholm and Hamburg.
The XlVth World Congress, to be held in Madrid, aims to be an open forum for all persons involved in risk
prevention at work, safety and health safety specialists, occupational health physicians, labour inspectors,
persons directly concerned with safety and health at work, including entrepreneurs and managers in
enterprises, trade union representatives, manufacturers and importers, as well as heads of public adminis-
tration and social security administrators.
The main focus of this Congress will be on the consequences for occupational safety and health of
processes of international and regional integration (e.g. EU, NAFTA) and of the globalization of economic
relations, on an in-depth analysis of chemical risks and on new proposals for cooperation and participa-
tion within enterprises. Other specific issues will also be dealt with, such as training and information, con-
trol ofworking conditions or new responsibilities. Special emphasis will be placed on small and medium-
sized enterprises and sectors facing specific problems with regard to safety and health at work, such as
the construction sector and agriculture.
In addition, as part of this Congress, the International Section "Electricity" of the ISSA will be organizing the
3rd International Film and Video Festival on Occupational Safety and Health.
Should you require any further information, please contact:
Secretaria del Congreso
Institute Nacional de Seguridad e Higiene en el Trabajo
Calle de Torrelaguna, 73
E-28027 Madrid-Spain
Tel. 34-1-404 57 36 FAX 43-1-326 78 55